Abstract:Objectives To examine the inhibitory effects of adenosine monophosphate-activated protein kinase (AMPK) activation on cardiomyocyte hypertrophy in vitro and to investigate the underlying molecular mechanisms. Methods Cultured neonatal rat cardiomyocytes were treated with the specific AMPK activator 5-aminoimidazole-4-carboxamide ribonu-cleoside (AICAR, 0.5 mmol/L) and the specific AMPK antagonist Compound C (1 μmol/L), and then stimulated with angiotensin II (Ang II, 1 μmol/L). The Muscle atrophy F-box (MAFbx)-small interfering RNA (siRNA) was transfected into cardiomyocytes using Lipofectamine 2000. The surface area of cultured cardiomyocytes was measured using planimetry. The protein degradation was determined using high performance liquid chromatogra-phy (HPLC). The expression of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), MAFbx, as well as the phosphorylation levels of AMPK and Forkhead box O 3a (FOXO3a), were separately measured using Western blot or real-time polymerase chain reaction. Results Activation of AMPK by AICAR inhibited Ang II-induced increase in cardiomyocyte area (P < 0.01 vs Ang II group), ANP and BNP protein expression (P < 0.01 vs Ang II group), as well as Ang II-induced decrease in protein degradation (P < 0.01 vs Ang II group). Compared with the control group, Ang II treatment significantly increased the p-FOXO3a level, whereas down-regulated MAFbx mRNA and protein expression levels in cultured cardiomyocytes (P < 0.01). Furthermore, AMPK activation decreased the p-FOXO3a level, increased the activity of transcription factor FOXO3a and up-regulated downstream atrogene MAFbx mRNA and protein expression (P < 0.05 vs Ang II group). Treatment of hypertrophied cardiomyocytes with Compound C blocked the effects of AMPK on cardiomyocyte hypertrophy and changes to the FOXO3a/MAFbx pathway (P < 0.05 vs Ang II + AICAR group). The effects of AICAR on cardiomyocyte hypertrophy were also blunted after MAFbx was silenced by transfection of cardiomyocytes with MAFbx-siRNA (P < 0.01 vs Ang II + AICAR group). Conclusions The present study demonstrates that AMPK activation inhibits cardiomyocyte hypertrophy by modulating the atrophy-related FOXO3a/MAFbx signaling pathway in vitro.

Activation of AMPK Inhibits Cardiomyocyte Hypertrophy by Modulating of the FOXO1/MuRF1 Signaling Pathway in Vitro

GW24-e2121 Adenosine Monophosphate-Activated Protein Kinase Attenuates Cardiomyocyte Hypertrophy Through Regulation of FOXO3a/MAFbx Signalling Pathway

Long-Term Activation of Adenosine Monophosphate-Activated Protein Kinase Attenuates Pressure-Overload-Induced Cardiac Hypertrophy

AMPK Attenuates Microtubule Proliferation in Cardiac Hypertrophy.

Limiting Cardiac Ischemic Injury by Pharmacological Augmentation of Macrophage Migration Inhibitory Factor–AMP-Activated Protein Kinase Signal Transduction

Abstract 17221: AMPK Regulation of Microtubule Dynamics in Cardiac Hypertrophy

Adenosine Kinase Regulation of Cardiomyocyte Hypertrophy

AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation

Asiatic Acid Protects Against Cardiac Hypertrophy Through Activating Ampka Signalling Pathway

Small molecule QF84139 ameliorates cardiac hypertrophy via activating the AMPK signaling pathway

A Pharmacological Activator of AMP-Activated Protein Kinase Protects Hypoxic Neurons in a Concentration-Dependent Manner

Abstract 21116: Adenosine Kinase Regulation of Cardiomyocyte Hypertrophy

Aerobic Exercise Activates AMPK/PGC-1α Pathway, Inhibits Cardiomyocyte Apoptosis Improves Mitochondrial and Infarcted Heart Function

Alpha1 catalytic subunit of AMPK modulates contractile function of cardiomyocytes through phosphorylation of troponin I

AMPK blunts chronic heart failure by inhibiting autophagy.

Regulatory effect of AMP-activated protein kinase on pulmonary hypertension induced by chronic hypoxia in rats: in vivo and in vitro studies

AMP-activated Kinase Activation Inhibits Transforming Growth Factor-Β1 Production in Cardiac Fibroblasts Via Targeting C/EBPβ

AMPK Activation Alleviates Myocardial Ischemia-Reperfusion Injury by Regulating Drp1-Mediated Mitochondrial Dynamics

Inhibition of the AMP-activated Protein Kinase-Α2 Accentuates Agonist-Induced Vascular Smooth Muscle Contraction and High Blood Pressure in Mice.

Regulation of miR-199a expression by AMPK in cardiac tissues

Anti-apoptotic effects of myocardin-related transcription factor-A on rat cardiomyocytes following hypoxia-induced injury